April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Rescue Therapy With Combined Anti-vegf And Pdt For Refractory AMD
Author Affiliations & Notes
  • Kevin R. Tozer
    Ophthalmology, USC/Doheny Eye Institute, Los Angeles, California
    VMR Institute, Huntington Beach, California
  • Lawrence Chong
    Ophthalmology, USC/Doheny Eye Institute, Los Angeles, California
    VMR Institute, Huntington Beach, California
  • Srinivas R. Sadda
    Ophthalmology, USC/Doheny Eye Institute, Los Angeles, California
  • Footnotes
    Commercial Relationships  Kevin R. Tozer, None; Lawrence Chong, None; Srinivas R. Sadda, None
  • Footnotes
    Support  Research to Prevent Blindness; NIH Grant # EY03040
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1671. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kevin R. Tozer, Lawrence Chong, Srinivas R. Sadda; Rescue Therapy With Combined Anti-vegf And Pdt For Refractory AMD. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1671.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Examine the efficacy of combination anti-VEGF and photodynamic therapy for the treatment of neovascular AMD refractory to anti-VEGF monotherapy.

Methods: : Retrospective interventional study. Study patients consisted of a subset of all patients treated at the VMR Institute and the Doheny Eye Institute with anti-VEGF monotherapy for neovascular AMD and considered treatment failures between January 1, 2009 and December 30, 2010. Treatment failure was defined as persistent subretinal or intraretinal fluid after at least 3 anti-VEGF injections in the 7 months prior to combination treatment. Combination treatment consisted of anti-VEGF intravitreal injection followed 7 to 14 days later by half fluence photodynamic therapy. Primary outcome measure was resolution of subretinal or intraretinal fluid by spectral domain OCT. Secondary outcome measures were visual acuity and frequency of repeat treatments with anti-VEGF monotherapy or combination therapy. All patients had at least 3 months of follow-up at time of abstract submission.

Results: : Nine eyes from nine patients were included in this study. Mean follow-up was 9.2 months (3-20 months). These patients received a mean of 5.3 injections (35 lucentis, 13 avastin) within the 12 months prior to declaration of treatment failure. After rescue combination therapy, a mean of 1.9 retreatments were administered (13 lucentis, 6 avastin, 4 combination retreatments). At one month after combination treatment, subretinal or intraretinal fluid resolved completely in 4 eyes, improved in 3 eyes and was unchanged in 2 eyes. Mean visual acuity was .85 logmar (20/140) before rescue therapy, .70 (20/100) at one month, and .75 (20/100-2) at 3 months. The mean interval between injections increased from 2.3 months to 3.89 months after combination therapy.

Conclusions: : Rescue therapy with the combination of Anti-VEGF and PDT is effective for eyes which fail Anti-VEGF monotherapy. Most patients experienced a decrease in subretinal fluid, improvement in visual acuity, and longer period between injections after patients receive combination therapy. Larger studies are needed to confirm these results.

Keywords: age-related macular degeneration • vascular endothelial growth factor • photodynamic therapy 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.